ACTRN12621000011886
46 evidence topics · 3 sources
Objective
Aims of the first-in-human and multiple-dose studies
“The aim of the studies was to assess the safety, tolerability, PK, pharmacodynamics (PD), and the effect of a high‐calorie breakfast of single and multiple oral doses of ESK‐001 in healthy adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-finding purpose of the wide dose range
Location and study date
Study period and site of the first-in-human study in the publication
“This was a first‐in‐human, phase I, single‐center, randomized, double‐blinded, placebo‐controlled, single (SAD) and multiple ascending dose (MAD) study of oral ESK‐001 administration in healthy participants (ACTRN12621000011886), conducted between January 21, 2021 and February 24, 2022 at a facility in Adelaide (Australia).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registration, enrollment, and data collection dates in the ANZCTR record
| Field | Quoted record |
|---|---|
| Date submitted | “26/11/2020” |
| Date registered | “11/01/2021” |
| Type of registration | “Prospectively registered” |
| Recruitment status | “Completed” |
| Date of first participant enrolment, anticipated | “29/01/2021” |
| Date of first participant enrolment, actual | “17/02/2021” |
| Date of last participant enrolment, anticipated | “17/11/2021” |
| Date of last participant enrolment, actual | “19/01/2022” |
| Date of last data collection, anticipated | “30/11/2021” |
| Date of last data collection, actual | “4/02/2022” |
| Date last updated | “14/06/2022” |
Recruitment state and principal investigator site in Adelaide, Australia, in the ANZCTR record
| Field | Quoted record |
|---|---|
| Recruitment state(s) | “SA” |
| Principal investigator | “Prof Sepehr Shakib” |
| Principal investigator address | “CMAX Clinical Research Pty Ltd Level 5, 18 a North Terrace Adelaide, SA, 5000 Australia” |
Results documents and data sharing in the ANZCTR record
| Field | Quoted record |
|---|---|
| Will the study consider sharing individual participant data? | “No” |
Study design
Study type, allocation, control, and phase in the ANZCTR record
| Field | Quoted record |
|---|---|
| Health condition(s) studied | “Psoriasis” |
| Study type | “Interventional” |
| Purpose of the study | “Treatment” |
| Allocation to intervention | “Randomised controlled trial” |
| Control group | “Placebo” |
| Phase | “Phase 1” |
Secondary sponsor, funding, and ethics approval in the ANZCTR record
| Field | Quoted record |
|---|---|
| Funding source category | “Commercial sector/Industry” |
| Secondary sponsor name | “Avance Clinical Pty Ltd” |
| Ethics committee name | “Bellberry Human Research Ethics Committee” |
| Ethics approval date | “10/12/2020” |
| Ethics approval number | “2020-11-1116” |
Regulatory framework of the Australian study
“The study adhered to the applicable regulations of the Australian Therapeutic Goods Administration under the Clinical Trial Notification scheme, the principles of the Declaration of Helsinki, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 (R2) Good Clinical Practice – Scientific Guideline, and the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding and randomization procedures
“The Sponsor, Principal Investigator, clinical study personnel, and study participants were blinded to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Any analysis of PK and PD data prior to unblinding was performed by the unblinded bioanalytical laboratory and pharmacokineticist at Avance Biometrics who had no responsibility for data monitoring and management in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data were reblinded before being provided to any study personnel who were to remain blind.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization was prepared by unblinded statisticians using SAS Version 9.4 (or higher), provided to pharmacy staff involved in study drug dispensing, and maintained in a restricted access area.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single ascending dose part: confinement, escalation, and 3:1 randomization
“In the SAD part, the screening period from Day −28 to −2 was followed by admission of the participants to the facility from Day −1 to 3 (Day 4 for Cohort 25 mg) with dose administration on Day 1 and final safety assessments on Day 7 ± 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose escalation was based on the safety and PK results of the previous dose cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive a single oral dose of ESK‐001 or placebo (3:1) in fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect cohort: two periods separated by a washout
“Eight participants were allocated to the food effect (FE) cohort and were admitted to the facility from Day −1 to 8, with the first study drug administration on Day 1 (Period 1), followed by a 5‐day washout period and second dose administration on Day 6 (Period 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Final safety assessments occurred on Day 12 ± 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single ascending dose cohorts in the congress poster's design schematic
Eligibility criteria
Age, body mass index, and health criteria in the published report
“Eligible participants included adult men and women, aged 18–55 years (SAD/MAD) or 18–60 years (MD), with a BMI of 18.0–32.0 kg/m2, body weight ≥50 kg (SAD/MAD), and medically healthy as determined by physical examination, vital signs, conventional 12‐lead electrocardiogram (ECG), and routine laboratory parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women were of nonchildbearing potential or had a negative pregnancy test if childbearing potential and were not lactating.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key inclusion criteria and age limits in the ANZCTR record
Key exclusion criteria in the ANZCTR record
Treatment
Liquid formulation and matching placebo
“The active treatment was a liquid formulation of ESK‐001 (Batch number: JR‐C200609006‐FPF20001), while placebo contained the same excipients as the active treatment, with denatonium benzoate (Batch number: R086X0) instead of ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Planned and actual single ascending dose levels and starting dose basis
“Planned dose levels were in the range of 5–150 mg; actual dose levels were 5, 10, 17.5, 25, 50, and 100 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The starting dose was determined based on preclinical data and allometric scaling in accordance with FDA guidance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose escalation was based on the observed safety, pharmacokinetics data, and in vitro TYK2 pharmacodynamic marker levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect cohort dose of 25 mg fasted and after a high-calorie meal
Single ascending dose, food effect, and multiple ascending dose regimens in the ANZCTR record
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Primary and secondary outcomes in the ANZCTR record
Adverse event recording period and adverse events expected with TYK2 inhibitors in the ANZCTR record
Safety assessments in the published report
“Safety assessments included: (1) recording of treatment‐emergent adverse events (TEAEs) including serious TEAEs, TEAEs leading to death, and TEAEs leading to study drug and/or study discontinuation; (2) clinical laboratory parameters; (3) vital signs; (4) body weight (SAD/MAD); (5) ECG parameters; and (6) physical examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic sampling and urine and feces collection in the single ascending dose part
“Blood and urine samples were collected predose and at several timepoints postdose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the SAD part, urine samples were only collected for the Cohort 50 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Feces were also collected in the SAD/MAD study but not analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled in the single and multiple ascending dose parts
Absence of a formal sample size calculation
Description of analysis sets
Safety analysis set
“The safety analysis was based on all randomized participants who received at least 1 dose of the study drug and had at least 1 postdose safety assessment, and was conducted by actual treatment received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose proportionality and food effect analyses
“Dose proportionality was assessed using the power model with linear regression method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The FE was determined by comparing the PK of ESK‐001 in fed and fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Natural log‐transformed maximum concentration (C max) and area under curve (AUC) were analyzed by an analysis of variance (ANOVA) using PROC MIXED in SAS with treatment, period, and sequence as a fixed effect and participant as a random effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Incomplete recruitment of two cohorts during the COVID-19 pandemic
Withdrawal of two food effect cohort participants
“Two participants of the FE cohort discontinued the study drug and study due to TEAEs (see Safety and Tolerability results), that were indicative of a possible COVID‐19 infection, requiring isolation and withdrawal from the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Race, ethnicity, sex, and body mass index in the single ascending dose part
“Most participants were white, not Hispanic or Latin, male in the cohorts receiving ESK‐001 and female in the pooled placebo cohorts (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean BMI ranged from 21.7 to 26.6 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Absorption, half-life, dose proportionality, and volume of distribution after single doses
“Following single doses of 5 to 100 mg, ESK‐001 was rapidly absorbed with a median time to C max (T max) of 0.8–1.1 h and showed linear PK characteristics with low variability across the dose cohorts (Figure 3a, Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean terminal half‐life (t ½) was 7.5– 9.3 h and was consistent across the different dose levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The AUC from time zero to infinite time (AUC0–inf) and C max increased in a near dose‐proportional manner at doses of 5– 100 mg, and C max plateaued at doses of 50 mg and above, indicating that absorption of ESK‐001 was slowing down at higher doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean apparent distribution volume during the terminal phase (Vz/F) was high, ranging from 103 to 186 L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A similar PK profile was observed following multiple doses in the MAD part (Figure S2, Table S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma pharmacokinetic parameters by single ascending dose and food effect cohort
Urinary excretion of unchanged drug after a single 50 mg dose and multiple doses
“Urinary excretion of ESK‐001 was minimal following single 50 mg and multiple‐dose administration of ESK‐001, with mean percentage of unchanged drug excreted (%Fe) (coefficient of variation [CV%]) ranging from 0.42% (58%) to 0.93% (49%), and geometric mean renal clearance of unchanged drug from the plasma (CLr) (CV%) ranging from 53.4 (77%) to 101 mL/h (53%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect with the liquid formulation at 25 mg
“The AUC0–inf was similar under fed and fasted dose administration of 25 mg ESK‐001 (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, C max was reduced by ~50% and median T max increased from 0.75 h to 4 h under fed conditions, indicating that food slowed the absorption of ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although food slowed the absorption of ESK‐001, data suggest that ESK‐001 may be administered with or without food, as the bioavailability (AUC0–inf) of ESK‐001 was similar under fed and fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamic results of the multiple ascending dose part
“PD parameters were also assessed in the MAD part of the SAD/MAD study but are not discussed in this article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similar results on biomarker changes were observed in the MAD part of the SAD/MAD study (data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by single ascending dose cohort
Incidence, severity, relatedness, and discontinuations in the single ascending dose part
“In the SAD part, 37 (69.8%) participants experienced 105 TEAEs; 32 (78.0%) participants receiving ESK‐001 experienced 96 TEAEs and 5 (41.6%) participants receiving placebo experienced 9 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most TEAEs (94.3%) were mild in severity and a few moderate in severity (all following administration of ESK‐001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no dose‐related trends in the incidence and severity of TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants in the FE cohort discontinued the study drug and study due to TEAEs indicative of a possible COVID‐19 infection, one after 1 dose (fed) in Period 1 due to upper respiratory tract infection, and one after 1 dose (fasted) in Period 1 due to sinus congestion, cough, and sneezing, all mild in severity and not related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAE (reported in ≥30% of the participants in any group) by preferred term was a headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the cohorts receiving ESK‐001, most TEAEs were considered related to the study drug by the investigator; 25 (61.0%) participants receiving ESK‐001 experienced 55 TEAEs considered related to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two (16.6%) participants receiving placebo experienced 3 TEAEs considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no apparent treatment or dose‐related trends in the clinical laboratory results and no TEAEs arising from abnormalities in clinical laboratory results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety in the multiple ascending dose part
“For the MAD part, a similar safety profile as for the SAD part was observed (Table S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant receiving ESK‐001 (Cohort 10 mg q.d fasted) discontinued the study drug and study after 1 dose due to TEAEs of nausea and vomiting, both mild in severity and both considered related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths, serious and severe events, vital signs, and electrocardiograms across both phase 1 studies
“Overall, there were no deaths, serious TEAEs, nor severe TEAEs reported in either the SAD/MAD or MD studies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No clinically relevant changes were observed in vital signs, ECGs, and physical examination findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, there were no MACE, malignancies, venous thromboembolisms, or adverse trends in laboratory parameters observed, which are commonly associated with non‐selective JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac conduction and concentration-QTc analysis
“Per cardiodynamic analyses, ESK‐001 had no clinically relevant effect on cardiac conduction (i.e., the PR and QRS intervals).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the concentration‐QTc analysis, an effect on the placebo‐corrected change from baseline QTcF (QT interval corrected using Fridericia's method) exceeding 10 ms can be excluded within the observed range of ESK‐001 plasma concentrations up to ~ 1000 ng/mL (data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
- The authors note that the study provided short-term exposure data, so chronic effects such as cumulative toxicity were not captured.
- The multiple ascending dose part is reported in supplementary figures and tables, and its biomarker results and the concentration-QTc results are reported as data not shown.
- Participants were healthy adults dosed with a liquid formulation of ESK-001.
- Because of the COVID-19 pandemic, the 17.5 mg and 100 mg cohorts could not be filled to the planned 8 participants (N = 4 and N = 5 in the pharmacokinetic table), and 2 food effect cohort participants withdrew with TEAEs indicative of a possible COVID-19 infection.
- The article and the registry differ: the article reports 91 participants enrolled and a study conducted between January 21, 2021 and February 24, 2022; the ANZCTR record gives a final sample size of 87, a first enrolment on 17/02/2021, and a last data collection on 4/02/2022.
- No formal sample size calculation was performed. Feces were collected but not analyzed, and urine was collected only for the 50 mg cohort of the single ascending dose part.
- The ANZCTR record states that no documents have been uploaded by study researchers and answers No to whether the study will consider sharing individual participant data.
Short-term exposure in both phase 1 studies
“Some study limitations should be taken into consideration, including that both the SAD/MAD study and the MD study provided short‐term exposure data, and hence, chronic effects (eg, cumulative toxicity) were not captured (as mentioned above).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, long‐term safety studies are needed to further evaluate the safety of ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiple ascending dose part reported only in the supplement
“As this article focuses on the tablet formulation, details of the MAD part are not discussed in detail.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study details of the MAD part are described in Appendix S1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote